Medifocus Vision with Dr. Augustine Y. Cheung, PhD, President and CEO
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with approximately 100 issued and pending US and international patents:
1. The “Endo-thermotherapy Platform”, and
2. The “Adaptive Phased Array Microwave Focusing Platform”.
Based on these proprietary technology platforms, the Company has developed two advanced therapeutic products: the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer and the Prolieve® system for the treatment of BPH. The APA-1000 uses precisely focused and controlled microwave energy to shrink breast cancer tumors without side-effects on the surrounding tissues to produce better treatment outcomes. The Company has received regulatory approvals to complete the APA 1000’s pivotal Phase-III clinical trials, the final step before marketing approval. The U.S. FDA-approved Prolieve® System is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The Prolieve® System is the only minimally invasive treatment option for the symptoms of enlarged prostate in men indicated by the FDA as an in office treatment alternative to drug therapy. The Prolieve® System is a revenue generating product catering to the $8 billion non-surgical BPH drug market. The Company is currently focusing on marketing Prolieve® for the treatment of BPH and accelerating the APA 1000 breast cancer system’s Phase III study.
Dr. Augustine Y. Cheung, PhD (President and CEO)
Previously founder and CEO of Celsion Corporation in the US and professor at the University of Maryland, Dr. Cheung is a well known microwave expert and has presented papers internationally. He has raised significant capital in the past for Celsion and successfully developed multiple focused heat based tumor targeting cancer treatment devices and pharmaceuticals. Dr. Cheung received a PhD in Electrical Engineering, from the University of Maryland.